LRRC4 Orchestrates AP2A1-Containing Clathrin-Coated Vesicles to Disrupt Mitochondrial Cristae and Restrict

Yang Li1,2, Cheng Huang3, Liangqi Jiang1,2

  • 1Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.

Insights

LRRC4, a tumor suppressor, uses vesicles to remodel mitochondria, inhibiting glioblastoma (GBM) growth. This novel Golgi-mitochondria pathway offers a new therapeutic target for GBM.

Area of Science:

  • Cell Biology
  • Oncology
  • Mitochondrial Biology

Background:

  • Mitochondrial dynamics and metabolic homeostasis are crucial for glioblastoma (GBM) progression.
  • The role of membrane-bound organelles in mitochondrial remodeling in GBM is not well understood.

Purpose of the Study:

  • To identify novel regulators of mitochondrial remodeling in GBM.
  • To elucidate the mechanism by which LRRC4 suppresses GBM growth.
  • To explore the potential of targeting Golgi-mitochondria crosstalk for GBM therapy.

Main Methods:

  • Single-sample gene set enrichment analysis (ssGSEA) to establish a mitoDynamic score.
  • Transmission electron microscopy and Blue Native PAGE to analyze mitochondrial structure and complexes.
  • Functional assays and xenograft models to assess GBM proliferation and invasion.

Main Results:

  • LRRC4 was identified as a Golgi-anchored tumor suppressor downregulated in GBM, correlating with poor prognosis.
  • LRRC4 redirects AP2A1-containing clathrin-coated vesicles to the inner mitochondrial membrane, disrupting the MICOS complex and Mic60 expression.
  • This disruption leads to mitochondrial cristae collapse, impaired oxidative phosphorylation, excessive mitophagy, and suppressed GBM proliferation and invasion.

Conclusions:

  • A novel Golgi-mitochondria axis involving LRRC4 and clathrin-coated vesicles regulates mitochondrial architecture.
  • Targeting this axis represents a potential therapeutic strategy for GBM by exploiting mitochondrial vulnerabilities.

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...